[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Alignment Healthcare insider sale under 10b5-1 plan; sales were tax-withholding for vested RSUs. On 09/10/2025 Dawn C. Maroney reported three non-discretionary sales of Alignment Healthcare (ALHC) common stock. The reported transactions were: sale of 77,555 shares at a weighted-average price of $16.2293 (per-share sales ranged $15.74–$16.735), sale of 30,884 shares at a weighted-average price of $16.8555 (range $16.74–$17.24), and sales totaling 107,223 shares under a Rule 10b5-1 plan adopted 05/22/2025 at a weighted-average price of $16.4163 (range $16.03–$16.73). Following these transactions the reporting person beneficially owned 1,797,237 shares.

Positive

• Transactions executed under a Rule 10b5-1 plan, indicating pre-planned, non-discretionary sales
• Sales were primarily to cover tax withholding for vested RSUs, a routine compensation-related activity

Negative

• Insider beneficial ownership declined to 1,797,237 shares after the reported transactions
• Aggregate sell volume is sizable (total reported disposals: 215,662 shares) which reduces insider stake

Insights

Corporate Governance Expert

TL;DR: Insider sales were executed under a 10b5-1 plan and for tax-withholding on RSU vesting, indicating non-discretionary activity.

The filing shows Dawn Maroney, an officer, sold shares on 09/10/2025 primarily to cover tax withholding tied to RSU vesting and also under a 10b5-1 plan adopted 05/22/2025. Use of a pre-established trading plan reduces concerns about opportunistic timing, but investors typically monitor aggregate insider holdings; the reporting person’s ownership declined to 1,797,237 shares after the transactions. This disclosure is routine for equity compensation settlements and governance transparency.

Securities Analyst

TL;DR: Transactions are material only as compensation-related liquidity events, not operational signals about ALHC fundamentals.

The three reported sales (77,555; 30,884; 107,223 shares) were executed at weighted-average prices in the $15.74–$17.24 ranges. The filer committed to provide detailed per-trade prices upon request. Because the filing states these were to cover tax withholding and under a Rule 10b5-1 plan, the trades should be interpreted as routine equity-compensation activity rather than discretionary insider divestiture impacting company fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maroney Dawn Christine

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD.

SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2025		S		77,555(1)	D	$16.2293(2)	1,935,344	D
Common Stock	09/10/2025		S		30,884(1)	D	$16.8555(3)	1,904,460	D
Common Stock	09/10/2025		S(4)		107,223	D	$16.4163(5)	1,797,237	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This transaction does not represent a discretionary trade by the reporting person.

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.74 to $16.735. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.74 to $17.24. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

4. Date of Rule 10b5-1 plan adoption: 05/22/2025

5. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.03 to $16.73. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for Dawn C. Maroney	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did the ALHC insider report on Form 4?

Dawn C. Maroney reported three sales on 09/10/2025: 77,555 shares, 30,884 shares, and 107,223 shares, all disposals of common stock.

Were the ALHC insider sales discretionary or part of a trading plan?

The filing indicates the sales were non-discretionary, including sales to cover tax withholding for vested RSUs and transactions under a Rule 10b5-1 plan adopted 05/22/2025.

At what prices were the ALHC shares sold?

Weighted-average prices reported: $16.2293 (range $15.74–$16.735), $16.8555 (range $16.74–$17.24), and $16.4163 (range $16.03–$16.73).

How many ALHC shares does the reporting person own after these trades?

Beneficial ownership after the transactions was reported as 1,797,237 shares.

Why did the filing state detailed per-trade pricing ranges?

The filer sold shares in multiple transactions and provided weighted-average prices, offering to disclose per-trade counts and prices to the company, shareholders, or the SEC upon request.